The global post-operative cataract surgery inflammation treatment market is expected to be worth $4.56 billion by 2023. According to Future Market Insights, the market will grow at a 6.77% CAGR until 2033, with a market value of $8.78 billion.
The rising number of cortical necrosis therapeutics are being delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries creates opportunities for market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
A lack of qualified personnel who are unable to treat the patients with appropriate treatments could curb the growth of the global cataracts market over a forecast period. The huge expenditure associated with the treatment of cataracts surely hampers market growth. Increased approvals from FDA and more clinical research associated with cataracts are boosting the market growth. For instance, EyePoint Pharmaceuticals received FDA approval for Dexycu intraocular suspension in February 2018. This suspension is given as a single dose at the end of cataract surgery for the management of postoperative inflammation. The approval will help people across the world who are severe experiencing complications after cataract surgery. This boosts market growth.
To remain ahead of your competitors, request a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-16994
The prevalence of ocular pain keeps showing a surge in growth as chemical industries and pollution around the world are growing. Chemical burns and flash burns cause significant and severe ocular pain due to irritations over the eye surface. Style and blepharitis lead to severe ocular pain as they cause eye and oil glands to be more sensitive around the area.
Key Takeaways from the Market Study
- The market value in 2022 was US$ 4.045 Billion.
- The global post-operative cataract surgery inflammation treatment grew at a CAGR of 6.45% from 2018 to 2022.
- Increased approvals from FDA and more clinical research associated with cataracts are boosting the market growth.
- UK-based subsidiary of Japanese ophthalmology firm Santen Pharmaceutical has announced the launch of Ducressa.
- Allay Therapeutics, reported the first-ever clinical data showing non-opioid pain relief lasting two weeks after a single administration.
- North America is said to dominate the market share followed by Asia-Pacific.
Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-16994
Competitive Landscape
Some of the prominent players in the post-operative cataract surgery inflammation drug treatment market are-
- Mallinckrodt Pharmaceuticals
- Salix Pharmaceuticals
- GlaxoSmithKline plc.
- Pfizer Inc.
- ASKA Pharmaceutical Co., Ltd.
- Bausch Health
- Johnson & Johnson Services, Inc.
- Janssen Global Services
- Takeda Pharmaceutical Company Limited
- Merck & Co., Inc.
Some of the important developments of the key players in the market are:
- In October 2022, Regeneron Pharmaceuticals, Inc. announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for EYLEA (aflibercept) Injection to treat Retinopathy of Prematurity (ROP) in preterm infants. This development helps the organization in developing its brand image in the ophthalmology market, among others.
- In May 2022, Reichert, Inc. has launched its redesigned refractometers & analytical instruments website with a vastly improved user experience.
For in-depth competitive analysis, Buy Now – https://www.futuremarketinsights.com/checkout/16994
More Valuable Insights Available
Future Market Insights offers an unbiased analysis of the global intraocular lymphoma treatment market, providing historical data for 2018-2022 and forecast statistics from 2023-2033.
To understand opportunities in the intraocular lymphoma treatment, the market is segmented based on drug type (Antibiotics, Amino Salicylates, Corticosteroids, Immunomodulators, Others), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies) and across major regions (North America, Latin America, Europe, Asia Pacific, and Middle East & Africa).
More Trending Reports by Future Market Research:
Bacteriophage Market Demand: The bacteriophage market is capturing a valuation of US$ 45.07 million in 2023 and is predicted to reach US$ 68 million by 2033. The market is likely to register a CAGR of 4.2% during the forecast period.
Pharmaceutical Lipids Market Trend: The pharmaceutical lipids market is anticipated to expand its roots at an average CAGR of 5.0% during the forecast period. The market is likely to hold a revenue of US$ 4.93 billion in 2023 while it is anticipated to cross a value of US$ 8.04 billion by 2033.
Fecal Pancreatic Elastase Testing Market Sales: The fecal pancreatic elastase testing market is expected to increase from US$ 15,306.7 million in 2023 to US$ 31,842.3 million by 2033. The market is likely to capture a 7.6% CAGR from 2023 to 2033.
About FMI:
Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs
